ACCR REPORTABLE LIST ICD-9 Casefinding Codes for ICD-O-3 Reportable Diseases Effective dates: October 1, 2014, September 30, 2015.

The following ICD-9-CM list is intended to assist in reportable neoplasm casefinding activities. It should be used to identify potentially reportable tumors. Any reportable neoplasms diagnosed on or after January 1, 1996 should be reported to the Arkansas Central Cancer Registry

Reportable Neoplasms:  Malignant neoplasms (exclusions noted below)  Benign and borderline neoplasms of the central nervous system (Cases diagnosed on or after January 1, 2004)  Carcinoma in-situ (exclusions noted below)  Carcinoid, NOS (excluding appendix, unless stated to be malignant)  Pilocytic/juvenile astrocytoma is listed as 9421/1 in ICD-0-3, is reportable and should be coded to 9421/3  Squamous intraepithelial neoplasia grade III of vulva (VIN), vagina (VAIN), and anus (AIN) beginning with 2001 cases  Primary tumors that originate in a mucous membrane are reportable and include the following: Lip, Anus, Labia, Clitoris, Scrotum, Vulva, Vagina, Prepuce and Penis

140.0-208.9 Malignancies (primary and secondary)

209.0-209.30 Neuroendocrine tumors

203.1 Plasma cell leukemia (9733/3)

205.1 Chronic neutrophilic leukemia (9963/3)

209.36 Merkel cell carcinoma of other sites 209.70 – 209.79 Secondary Neuroendocrine/Carcinoid tumors 225.0-225.9 Benign neoplasm of brain and spinal cord 227.3-227.4 Benign Pituitary gland and craniopharyngeal duct (pouch), pineal gland 228.02 Hemangioma; of intracranial structures 228.1 Lymphangioma, Note: Includes only lymphangioma of the brain, other parts of nervous system and endocrine gland. 230.0-231.9 Carcinoma in-situ of digestive organs and respiratory system 233.0-234.9 Carcinoma in-situ of breast and genitourinary system; other and unspecified sites 237.0-237.9 Neoplasms of uncertain behavior of endocrine glands and nervous system 237.70-237.72 Neurofibromatosis, unspecified, one, two vonRecklinghausen’s Disease 238.4 Polycythemia vera (9950/3) 238.6 Solitary plasmocytoma (9731/3), Extramedullary plasmacytoma (9734/3) 238.71-238.76 Essential thrombocythemia (9960/3-9962/3, 9985/3, 9986/3, 9987/3) 239.6-239.7 Neoplasms of uncertain nature brain, endocrine glands and other parts of nervous system 259.2 Carcinoid Syndrome 273.2 Gamma Heavy Chain Disease; Franklins Disease 273.3 Waldenstrom’s macroglobulinemia 285.0 Sideroblastic Anemia (9982/3-9984) 288.3 Hypereosinophilic syndrome (9964/3) 288.4 Hemophagocytic syndrome (9751/3, 9754/3) 289.83 Myelofibrosis (9961/3) 789.51 Malignant ascites V58.0 Encounter or admission for radiotherapy V58.1 Encounter for chemotherapy and immunotherapy Neoplasms not required by ACCR: Morphology Codes Diagnosis/Terminology 8000-8004 Neoplasms, malignant, NOS of skin 8010/2 Carcinoma in-situ of cervix (CIS) 8010-8045 Epithelial carcinomas of the skin 8050-8084 Papillary and squamous cell carcinoma of skin 8077/2 Squamous Intraepithelial Neoplasia, grade III of cervix (CIN III) 8090-8110 Basal cell carcinoma of the skin 8148/2 Prostatic Intraepithelial Neoplasia

- Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries which moved from /3 to /1 are NOT collected as of 1/1/2001

The following terms are synonymous with in-situ disease (Behavior code 2)

Adenocarcinoma in an adenomatous polyp with no invasion of stalk Clark’s level I melanoma or limited to epithelium Noninfiltrating comedocarcinoma, confined to epithelium Hutchison’s melanotic freckle NOS, intracystic-noninfiltrating, intraductal, intraepithelium NOS, intraepidermal NOS (involvement up to but not Including basement membrane.) Lentigo maligna, lobular neoplasia, lobular-noninfiltrating, noninvasive, no stromal involvement, papillary noninfiltrating or intraductal Vaginal intraepithelial neoplasia Grade III or VAIN III Vulvar intraepithelial neoplasia Grade III or VIN III Anal intraepithelial neoplasia Grade III or AIN III ◊ If any invasion is present, no matter how limited – cases must be coded to invasive behavior ◊ If other benign or borderline diseases are required to be collected by your hospital cancer committee or other appointed officials, they are not required to be reported to ACCR.

Revised 8/18/2015